AWS
VRTX icon

Atria Wealth Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

Atria Wealth Solutions’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.45M Sell
3,254
-3,402
-51% -$1.57M 0.03% 510
2025
Q1 		$3.23M Sell
6,656
-556
-8% -$259K 0.04% 465
2024
Q4 		$2.9M Sell
7,212
-2,523
-26% -$1.17M 0.03% 513
2024
Q3 		$4.53M Sell
9,735
-987
-9% -$474K 0.05% 376
2024
Q2 		$5.03M Buy
10,722
+107
+1% +$46.4K 0.06% 344
2024
Q1 		$4.44M Buy
10,615
+21
+0.2% +$8.88K 0.05% 373
2023
Q4 		$4.31M Buy
10,594
+8
+0.1% +$2.96K 0.05% 353
2023
Q3 		$3.68M Buy
10,586
+200
+2% +$69.9K 0.05% 373
2023
Q2 		$3.65M Buy
10,386
+830
+9% +$280K 0.05% 372
2023
Q1 		$3.01M Buy
9,556
+732
+8% +$220K 0.04% 405
2022
Q4 		$2.55M Sell
8,824
-776
-8% -$237K 0.04% 431
2022
Q3 		$2.78M Buy
9,600
+5,009
+109% +$1.44M 0.05% 374
2022
Q2 		$1.29M Sell
4,591
-1,435
-24% -$384K 0.02% 588
2022
Q1 		$1.57M Buy
+6,026
New +$1.43M 0.03% 557

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Atria Wealth Solutions's VRTX Position: Q2 2025 in Review

Atria Wealth Solutions reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q2 2025, selling an estimated $1.57M and leaving 3,254 shares worth $1.45M. The position accounts for 0.03% of the portfolio, ranked #510.

Atria Wealth Solutions first reported a position in VRTX in Q1 2022 and has held it in 14 quarters since. The position peaked at $5.03M in Q2 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Atria Wealth Solutions held 3,254 shares of Vertex Pharmaceuticals worth $1.45M as of Q2 2025.
  • Atria Wealth Solutions sold 3,402 Vertex Pharmaceuticals shares in Q2 2025, an estimated $1.57M.
  • Vertex Pharmaceuticals made up 0.03% of Atria Wealth Solutions's portfolio in Q2 2025, its #510 holding.
  • Atria Wealth Solutions first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Atria Wealth Solutions's Vertex Pharmaceuticals position peaked at $5.03M in Q2 2024.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.